Shares in Clearside Biomedical (NSDQ:CLSD) rose today after the biopharmaceutical company met expectations on Wall Street with its 3rd quarter results.
The Alpharetta, Ga.-based company posted losses of -$5.6 million, or -28¢ per share, on sales of $5,000 for the 3 months ended Sept. 30. This is the 1st quarter that Clearside has reported revenue.
Get the full story at our sister site, Drug Delivery Business News.
The post Clearside tops Q3 estimates, posts license revenue appeared first on MassDevice.